Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of the monoclonal antibody drug class that has led to several deaths.

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...

Leqembi — sold through a partnership between Eisai and Biogen Inc. — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s memory.

Leqembi is the second Alzheimer's treatment from Eisai and Biogen to come under FDA review, after the controversial approval of the drug Aduhelm in the summer of 2021.

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union Apr. 15, 2025 7:00 PM ET Biogen Inc. (BIIB) ...